My hair had changed,” he says. “It was lifeless and much thinner. My dad was mostly bald at 60, and I could see myself on the ...

StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug ...

Singapore, Singapore, November 22nd, 2024, ChainwireKipley.ai, an AI deployment solutions provider under the KIP Group, has ...

Alloy Therapeutics inks collaboration & license agreement with Takeda to develop cell therapy platform: Tokyo Friday, November 22, 2024, 17:00 Hrs [IST] Alloy Therapeutics Inc. (A ...

Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...

ALBANY – Albany State University has received three grants from the National Science Foundation totaling more than $3.6 million. “These grants represent a significant investment in our research ...

Dynamic, reversible modifications of DNA and RNA regulate how genes are expressed and transcribed, which can influence ...

Dr. Roxana Redis: Retinal organoids have shown remarkable promise, especially in cases where traditional models fall short.

Phillips 66 (PSX), the Houston-based oil giant, faces legal trouble after a federal grand jury indicted the company for violating the Clean Water Act. The charges stem from the release of nearly ...

A new approach for identifying new cellular RNA targets of snoRNAs uncovered thousands of previously unknown targets ...

iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA ... Takeda’s proprietary induced pluripotent stem cell ...

The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval in 2018 for patients who had been treated with apixaban or rivaroxaban.